CSPC's HD1916 Matches Wegovy for Weight Loss in Phase 3 Obesity Trial
Start here
CSPC Pharmaceutical Group's HD1916, a chemically synthesized semaglutide injection, met its prespecified equivalence margin for weight loss against Wegovy in a Phase 3 obesity study. The results were published in Diabetes, Obesity and Metabolism (PMID: 42839752). The trial tested therapeutic equivalence to the comparator rather than superiority, positioning HD1916 as a potential alternative to Novo Nordisk's original biologically derived semaglutide. Open questions include regulatory submissions and approvals, pricing and market access, and whether HD1916's chemical synthesis route translates into manufacturing or cost advantages.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickCSPC's HD1916 Meets Equivalence to Wegovy in Phase 3 Obesity Trial Published in Diabetes, Obesity and Metabolism
CSPC Pharmaceutical Group's HD1916, a chemically synthesized semaglutide injection, showed therapeutic equivalence to Wegovy in a Phase 3 obesity study published in Diabetes, Obesity and Metabolism (PMID: 42839752). The trial met its prespecified equivalence margin for weight loss versus the comparator.
Coverage and heat for this story
Reports so far 1·Heat now 5·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.